ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.720,01
-1,47%
S&P 500
5.702,55
-0,19%
Dow Jones
42.063,36
0,09%
Euro vs US Dollar
1,11755
0,15%
Bitcoin
63.172,70
0,35%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. BeyondSpring Inc (BYSI)

  7. BeyondSpring Inc (BYSI) News

BYSI

BeyondSpring (BYSI)

BeyondSpring Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BYSI
DatumZeitQuelleÜberschriftSymbolFirma
16/09/202413h00GlobeNewswire Inc.BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024NASDAQ:BYSIBeyondSpring Inc
16/09/202413h00GlobeNewswire Inc.BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024NASDAQ:BYSIBeyondSpring Inc
10/09/202413h00GlobeNewswire Inc.BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory MediciNASDAQ:BYSIBeyondSpring Inc
03/09/202413h00GlobeNewswire Inc.BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, PlinabulinNASDAQ:BYSIBeyondSpring Inc
29/08/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
06/08/202414h24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
06/08/202413h00GlobeNewswire Inc.SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology IndicationsNASDAQ:BYSIBeyondSpring Inc
15/07/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BYSIBeyondSpring Inc
12/06/202423h11Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BYSIBeyondSpring Inc
12/06/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
12/06/202414h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BYSIBeyondSpring Inc
16/05/202414h00GlobeNewswire Inc.BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
03/05/202413h00GlobeNewswire Inc.BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
29/04/202423h30GlobeNewswire Inc.BeyondSpring Provides Business Update and Reports Year End 2023 Financial ResultsNASDAQ:BYSIBeyondSpring Inc
29/04/202423h30GlobeNewswire Inc.BeyondSpring Files 2023 Annual Report on Form 20-FNASDAQ:BYSIBeyondSpring Inc
25/03/202412h00GlobeNewswire Inc.BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerNASDAQ:BYSIBeyondSpring Inc
26/02/202414h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
26/02/202414h00GlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing RequirementsNASDAQ:BYSIBeyondSpring Inc
14/02/202422h30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BYSIBeyondSpring Inc
02/02/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
16/01/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
10/01/202421h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
10/01/202421h00GlobeNewswire Inc.BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-KNASDAQ:BYSIBeyondSpring Inc
18/12/202322h31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
18/12/202322h30GlobeNewswire Inc.BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNASDAQ:BYSIBeyondSpring Inc
07/11/202313h00GlobeNewswire Inc.BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 InhibitorsNASDAQ:BYSIBeyondSpring Inc
31/10/202313h00GlobeNewswire Inc.BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere ModelsNASDAQ:BYSIBeyondSpring Inc
30/10/202313h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
30/10/202313h00GlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:BYSIBeyondSpring Inc
26/10/202314h30GlobeNewswire Inc.SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” SymposiumNASDAQ:BYSIBeyondSpring Inc
 Showing the most relevant articles for your search:NASDAQ:BYSI

Kürzlich von Ihnen besucht

BIT
S29793
Societe Generale Effekten
BIT
UPVLD
Ubs Irl Etf Plcs Etf Usd...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten